ClinicalTrials.gg
RecruitingNCT07252440Updated Jul 16, 2026

A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease

A Phase 2 interventional study of TTYP01 tables 60mg and TTYP01 tables 90mg in AD and Early Alzheimer's Disease, sponsored by Shanghai Auzone Biological Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Shanghai Auzone Biological Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Planned enrollment
61st of 176
180 · median 100
Started
2025
with 40 others
Phase 2
20 of 260
7 open now
Primary completion
2028-10
later than 120 of 161 live
Registered
208th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 61st largest by planned enrollment of the 176 interventional ones that give a count, is one of 41 that started in 2025, is one of 20 in phase 2, reaches primary completion later than 120 of the 161 other live ones, and was the 208th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled parallel Phase II core period study to evaluate the efficacy and safety of TTYP01 Tablets in early symptomatic AD (Mild cognitive impairment [MCI] due to AD, or mild AD dementia).

A total of 180 participants will be randomized into 3 parallel groups: 2 TTYP01 dose groups and 1 placebo group.

03

Conditions studied

  • AD
  • Early Alzheimer's Disease

Browse trials for

Keywords

  • AD
  • Alzheimer's Disease
  • TTYP01
  • Placebo-Controlled
  • Double-Blind
  • Early Alzheimer's disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all the following criteria to be eligible for this study:

  1. Age between 55 and 85 years (inclusive, based on the date of signing the ), applicable to all genders.
  2. Must meet the 2024 NIA-AA revised criteria for diagnosing MCI due to AD or mild AD dementia.
  3. CDR score: At screening and baseline, the CDR-GS must be 0.5 or 1.0, and the CDR memory score must be0.5 or higher.
  4. score: At screening, the MMSE score must be 20 or higher.
  5. (BMI): At screening, BMI must be greater than 17 and less than 35 (inclusive).
  6. History of memory decline: A history of at least 6 months of gradual and progressive memory decline prior to signing ICF must be reported and confirmed by an informant.
  7. Blood p-tau 217: positive.
  8. Aβ- PET scan: Visual read of Aβ-PET scan must be positive.
  9. Study partner: Must have a designated study partner who can support the participants and spend at least 8 h per week with them during the study. The partner must provide a separate written informed consent and be willing and able to provide follow-up information about the participant. They should regularly spend enough time with the participants to reliably meet study requirements. The study partner does not need to live with the participant but should be easily reachable during the study. If the partner is unable to continue supporting due to health or other reasons, it is allowed to replace with another eligible partner. The replacement partner must provide a separate written informed consent and be willing and able to provide follow-up information about the participant.
  10. Concomitant medication: Participants who are receiving cholinesterase inhibitors (donepezil, rivastigmine, galantamine, huperzine A, etc.) and/or memantine and other AD symptomatic treatment drugs for AD can be enrolled into the study, but must be on a stable dose for at least 4 weeks prior to baseline. For all other (i.e., non-AD-related) allowed concomitant medications, participants must receive a stable dose (not for topical, as needed [PRN], or discontinued medications) for at least 4 weeks prior to baseline unless otherwise stated.
  11. :

    a. Male participants i. Male participants, regardless of , if their non-pregnant female partner is a female of childbearing potential, must agree to maintain abstinence (if this is their preferred and usual lifestyle) or to use a barrier method and another highly effective (failure rate less than 1%) method of contraception (see Section 17.5 for details) until 90 days after the last dose of IP.

    ii. Male participants with pregnant partners should use condoms during intercourse for the duration of the study and until the end of the estimated relevant potential exposure for women of childbearing potential (WOCBP; expected to be 90 days after the last dose of IP).

    iii. Male participants should refrain from sperm donation for the duration of the study and until 90 days following the last dose of IP.

    b. Female participants i. WOCBP must use, or be willing to use, two forms of effective contraception (a barrier method and one other highly effective method of contraception, as detailed in Section 17.5) during participation in the trial and for 90 days after the last dose of the IP.

    ii. WOCBP potential is defined as those who are:

    ① Following menarche

    ② From the time of menarche until becoming unless permanently sterile (see below)

    • A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

      • In the absence of 12 months of amenorrhea, confirmation with more than one follicle-stimulating hormone (FSH) measurement is required.
      • Individuals receiving hormone replacement therapy (HRT) whose menopausal status is in doubt will be required to use a non-estrogenic, highly effective contraceptive method if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
    • Permanent sterilization methods and gender-affirming procedures (for the purpose of this study) include:

      • Documented hysterectomy
      • Documented bilateral salpingectomy
      • Documented bilateral oophorectomy
      • For individuals with permanent infertility due to an alternate medical cause other than the above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator discretion should be applied to determining study entry.

    iii. All WOCBP must be negative at Visit 1 based on a serum pregnancy test.

  12. Informed consent: Must obtain a voluntary signed ICF, approved by an Ethics Committee, from the participants or their legal representative before any study procedure.
  13. Language proficiency: Must be fluent in the language used at the study site.
  14. Protocol compliance: Must be willing and able to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria

Participants who meet any of the following exclusion criteria will not be eligible for the study:

  1. History of intracranial infection or traumatic brain injury, that is deemed unsuitable for this study based on the judgment by the investigators.
  2. Severe coronary heart disease, cardiac insufficiency ( Class Ⅲ and Class IV), atrial fibrillation, and other heart diseases that are deemed unsuitable for this study based on the judgment by the investigators.
  3. the last 3 years, with the exception of non- basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with a low risk of recurrence or spread.
  4. Severe hematologic disorders, such as myelodysplastic syndrome, aplastic anemia, lymphoma, leukemia, etc.
  5. Peptic ulcer or obstruction or other diseases that affect the absorption of oral medication.
  6. Any neurological disorder that may cause cognitive impairment beyond the impact of AD.
  7. Any psychiatric diagnosis or neuropsychiatric symptom (such as hallucinations, major depression, or delusions) that may interfere with the participant's study procedure.
  8. A history of (TIA), stroke, or seizure in the 12 months prior to signing ICF.
  9. The Hachinski Ischemic Index Scale (HIS) at screening > 4 points.
  10. at screening or at baseline showing prolonged [Fridericia correction formula, see Section 17.4] (QTcF > 480 ms in women; QTcF > 470 ms in men) that are deemed by the investigators, or other clinically significant abnormalities of the ECG that are considered by the investigator to be unsuitable for participation in a clinical study (e.g., heart rate \< 50 beats/min, sinus node lesions, Morse II or third-degree atrioventricular block, etc.).
  11. The Geriatric Depression Scale (GDS) score at screening ≥ 8 points.
  12. to MRI scans, including pacemakers/defibrillators, ferromagnetic metal implants (in addition to those approved for safe use in MRI scanners, such as cranial and cardiac devices).
  13. Contraindications with PET scanning, allergies to tracers.
  14. Brain MRI at screening reveals evidence of other clinically significant lesions, suggesting a possible diagnosis of dementia other than AD.
  15. Brain MRI at screening reveals the evidence of angioedema, severe white matter damage (Fazekas score = 3), etc., that are deemed unsuitable for this study based on the central imaging assessment; or those with clinically significant space-occupying lesions, aneurysms/vascular malformations, infarctions in critical areas, hydrocephalus, encephalomalacia, etc., that are deemed unsuitable for this study by the investigators.
  16. Participants with inadequately controlled bleeding disorder (including count \< 100×109/L or [INR] > 1.5), that are deemed clinically significant by the investigators.
  17. Participants with results of thyroid function tests that fall outside the normal range that are deemed clinically significant by the investigators.
  18. Laboratory test results for serum vitamin B12 levels below the normal range.
  19. Positive serological finding for (HIV), active syphilis, surface antigen (HBsAg), or virus (HCV) antibody.
  20. Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG present at screening or baseline that the investigator determines the situations that affected the safety of the participants or other interferences with the study.
  21. Have a known or suspected history of drug or alcohol abuse.
  22. Serious or unstable disease, or any other medical condition (e.g., heart, respiratory, gastrointestinal, liver, kidney, endocrine and nervous system disease, including poorly controlled hypertension, with a systolic blood pressure of ≥160mmHg or a diastolic blood pressure of ≥100 mmHg; Poorly controlled diabetes, etc.) that the investigator believes may affect the participant's safety or interfere with study evaluation.
  23. Previous use of prohibited drugs, including disease-modifying drugs (anti-amyloid antibodies, etc.), other formulations of edaravone or drugs containing edaravone.
  24. Have scheduled major surgical procedures requiring general anesthesia during the study period. For a scheduled procedure that requires only local anesthesia and performed as a day procedure without the need for post-operative hospitalization, participant does not need to be excluded if the investigator determines that the procedure does not interfere with study procedures or participant safety.
  25. Severe vision, hearing, reading, comprehension, or physical dysfunction that prevents the participant from accurately performing neuropsychological tests.
  26. Have been diagnosed with serious active liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc., or (ALT) > 2 × (ULN) or aspartate aminotransferase (AST) > 2 × ULN, or total (TBIL) > 1.5 × ULN.
  27. Have been diagnosed with severe active kidney disease, severe renal insufficiency; or \< 45 mL/min/1.73m² (Calculated based on the CKD-EPI formula, see Section 17.6 for details).
  28. Have severe systemic disease and is \< 2 years.
  29. Answer "yes" to C-SSRS suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before screening, at screening, or at the baseline visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before screening.
  30. Allergic to edaravone, sodium bisulfite, or soluplus (Note: Asthma patients are sensitive to sulfites and may have allergic reactions. For patients with a history of asthma, the investigator will carefully assess whether to enroll them.).
  31. History of major surgery within 4 weeks prior to the baseline, that is deemed as not yet fully recovered by the investigators.
  32. Have participated in, or are currently participating in, another clinical study within the 30 days prior to randomization (Participants who have previously participated in clinical studies of disease-modifying drugs targeting Aβ and/or tau pathology will follow exclusion criteria 23).
  33. Participants who have received cholinesterase inhibitors, memantine and/or other symptomatic treatment drugs for AD within 4 weeks prior to randomization and stopped treatment due to safety concerns or other reasons and refuse to or unable to receive it again.
  34. Female participants who are pregnant, breastfeeding, planning to become pregnant recently, or unwilling to use measures.
  35. Have other conditions that investigator believes the participant is unsuitable for this study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Low-dose group

    60 mg (2 TTYP01 30 mg tablets + 1 placebo tablet) BID

    Drug: TTYP01 tables 60mg

  • Active comparator
    High-dose group

    90 mg (3 TTYP01 30 mg tablets) BID

    Drug: TTYP01 tables 90mg

  • Placebo comparator
    Placebo group

    3 placebo tablets, BID

    Drug: TTYP01 tables 0mg

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) score at Week 78.

    Time frame: Baseline to Week 78

  2. Number of participants with Adverse events, serious adverse events, adverse events of special interest

    Time frame: Baseline to Week 78

Secondary outcomes

  1. TTYP01 PK parameter (AUC (0-t,0-24,∞)

    Time frame: 78 weeks

  2. Change From Baseline in Amyloid Positron Emission Tomography (PET) Using Centiloids at Week 39 and Week 78

    Time frame: Baseline to Week 39 and Week78

  3. Change from baseline in blood p-tau 217 at week 78.

    Time frame: baseline to week 78

  4. Changes from baseline in Mini-Mental State Examination (MMSE).

    Time frame: Week 13, 26, 39, 52, 65, and 78

  5. Change from Baseline in Alzheimer Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog13) at Week 39 and Week 78.

    Time frame: baseline to week 39 and week 78

Other outcomes

  1. To explore the exposure-clinical effect relationship of TTYP01 Tablets in treating early symptomatic AD.

    Correlation analyses between edaravone exposure in blood and changes of CDR-SB, ADCOMS, ADAS-Cog13, ADCS-ADL, and MMSE score at Week 78.

    Time frame: week78

  2. To explore the exposure-effect relationship of TTYP01 Tablets on cerebral amyloid plaque deposition, and MRI brain volume.

    Correlation analyses between edaravone exposure in blood and changes of Aβ-PET and MRI brain volume at Week 39 and Week 78.

    Time frame: week39 ,week78

  3. To assess the effect of TTYP01 vs. placebo on clinical progression, behavioral, neuropsychiatric symptom and study partner burden in early symptomatic AD patients.

    • The proportion of clinical progression or clinical improvement in the test group compared with the placebo group at Week 13, 26, 39, 52, 65, and 78. ①Progression criteria: 1. Any increase in CDR-GS from baseline; 2. CDR-SB is higher than baseline. Criteria 1 and 2 are evaluated separately. ②Improvement criteria: 1. Any decrease CDR-GS from baseline; 2. CDR-SB is lower than baseline. Criteria 1 and 2 are evaluated separately.

    Time frame: Week 13, 26, 39, 52, 65, and 78.

  4. To assess the effect of TTYP01 vs. placebo on clinical progression, behavioral, neuropsychiatric symptom and study partner burden in early symptomatic AD patients.

    • Time to clinical progression (criteria 1: time to increase in CDR-GS from baseline; 2: time to increase in CDR-SB from baseline).

    Time frame: Time to clinical progression,up to 78 weeks

  5. To assess the effect of TTYP01 vs. placebo on clinical progression, behavioral, neuropsychiatric symptom and study partner burden in early symptomatic AD patients.

    Changes in Neuropsychiatric Inventory (NPI) scores from baseline at Week 26, 52 and 78.

    Time frame: week26,52,78

  6. To assess the effect of TTYP01 vs. placebo on clinical progression, behavioral, neuropsychiatric symptom and study partner burden in early symptomatic AD patients.

    • Changes from baseline in the Zarit Burden Interview (ZBI) at Week 26, 52, and 78.

    Time frame: Week 26, 52, and 78.

  7. To evaluate the effects of TTYP01 Tablets on blood PD markers (AD biomarkers and cytokines).

    Changes from baseline in levels of AD biomarkers amyloid-beta peptides (Aβ42/40), Glial Fibrillary Acidic Protein (GFAP), and neurofilament light chain (NfL) at Week 4, 8, 13, 39 and 78. Changes in cytokines: interferon-gamma (IFN-γ), interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) at Week 4, 8, 13, 39 and 78

    Time frame: Week 4, 8, 13, 39 and 78.

  8. To evaluate the relationship between brain amyloid levels and blood biomarkers (including but not limited to blood p-tau 217, Aβ42/40, NfL, GFAP, and cytokines (IFN-γ, IL-1β, IL-6 and TNF-α) in participants with AD.

    Correlation between changes in brain amyloid levels (Aβ-PET), and changes in blood biomarkers (including but not limited to blood p-tau 217, Aβ42/40, NfL, GFAP and cytokines (IFN-γ, IL-1β, IL-6 and TNF-α).

    Time frame: week39,week78

  9. To evaluate the relationship between volume MRI (vMRI) and clinical changes (CDR-SB, ADCOMS, ADAS-Cog13, ADCS-ADL and MMSE) in participants with AD.

    Correlation between clinical changes (CDR-SB, ADCOMS, ADAS-Cog13, ADCS-ADL, and MMSE) and changes in vMRI.

    Time frame: week78

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 34 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 26, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Oct 23, 2028
CompletionEst.
Nov 23, 2028
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07252440
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Dec 19, 2025
Primary completion
Oct 23, 2028 (estimated)
Completion
Nov 23, 2028 (estimated)
Last update
Jul 16, 2026

Study contacts

Yan-Jiang Wang, MD, PhD
Contact
wayaja@163.com
+86-023-68757113

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTYP01

Start the discussion